Photo from Guenther Koehne/Linkedin
Jun 16, 2023, 18:43
This is a first in human clinical trial utilizing CD34+ selected allografts with gene-edited CD33neg hematopoietic stem cells from HLA matched related or unrelated donors for patients with AML – Guenther Koehne
It’s been my privilege to present first results of the VOR study VBP101, here at the European Hematology Association (EHA) 2023. This is a first in human clinical trial utilizing CD34+ selected allografts with gene-edited CD33neg hematopoietic stem cells from HLA matched related or unrelated donors for patients with AML. We reported a timely engraftment of all cell lineages of five patients transplanted with CD34+CD33- hematopoietic stem cells when compared to non-gene edited CD34+ selected allografts, thus providing a potential new platform of targeting CD33 expressing leukemia cells post allogeneic stem cell transplants.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14